Cargando…
Correction to: The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma
Autores principales: | Festuccia, C., Mancini, A., Colapietro, A., Gravina, G. L., Vitale, F., Marampon, F., Delle Monache, S., Pompili, S., Cristiano, L., Vetuschi, A., Tombolini, V., Chen, Y., Mehrling, T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5853051/ https://www.ncbi.nlm.nih.gov/pubmed/29540202 http://dx.doi.org/10.1186/s13045-018-0587-3 |
Ejemplares similares
-
The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma
por: Festuccia, Claudio, et al.
Publicado: (2018) -
The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma
por: Gravina, Giovanni Luca, et al.
Publicado: (2017) -
Multiple Antitumor Molecular Mechanisms Are Activated by a Fully Synthetic and Stabilized Pharmaceutical Product Delivering the Active Compound Sulforaphane (SFX-01) in Preclinical Model of Human Glioblastoma
por: Colapietro, Alessandro, et al.
Publicado: (2021) -
The Brain Penetrating and Dual TORC1/TORC2 Inhibitor, RES529, Elicits Anti-Glioma Activity and Enhances the Therapeutic Effects of Anti-Angiogenetic Compounds in Preclinical Murine Models
por: Gravina, Giovanni Luca, et al.
Publicado: (2019) -
P848: TINOSTAMUSTINE (EDO-S101), AN ALKYLATOR AND HISTONE DEACETYLASE INHIBITOR, ENHANCES THE EFFICACY OF DARATUMUMAB IN PRECLINICAL MODELS OF MULTIPLE MYELOMA
por: Diaz-Tejedor, A., et al.
Publicado: (2022)